Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ0D3V)

• Drug Name: GRC-6211 Drug Info
• Synonyms: Oxolinic acid; oxolinic acid; 14698-29-4; Nidantin; Prodoxol; Prodoxal; Emyrenil; Dioxacin; Gramurin; Oxolinic; Oksaren; Ossian; Uroxol; Utibid; Urotrate; Uritrate; Pietil; Oxoboi; Ultibid; Starner; Acido oxolinico; Uro-alvar; Acide oxolinique; Acidum oxolinicum; Cistopax; Tiurasin; Orthurine; Acido ossolico; 5-Ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; NSC-110364; Urinox; Acido ossolico [DCIT]; 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic acid; GRC-6127; TRPV1 antagonists (asthma), Glenmark/Lilly; TRPV1 antagonists (incontinence), Glenmark/Lilly; TRPV1 antagonists (pain), Glenmark/Lilly; Transient receptor potential vanilloid sub-family 1 (pain), Glenmark/ Lilly; Vanilloid receptor VR1 antagonists (incontinence/pain/asthma), Glenmark/Lilly

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 138393987
  TTD Drug ID: DMZ0D3V

Molecule-Related Drug Atlas

Drug(s) Targeting Transient receptor potential cation channel V1 (TRPV1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[4]
CNTX-4975	DMB4JPG	Knee osteoarthritis	FA01	Phase 3	[5]
XEN-D0501	DMG7PDY	Overactive bladder	GC50.0	Phase 2	[6]
Resiniferatoxin	DMP62L5	Neuropathic pain	8E43.0	Phase 2	[7]
PAC-14028	DM3816P	Atopic dermatitis	EA80	Phase 2	[8]
GRC-15300	DMWXJSZ	Pain	MG30-MG3Z	Phase 2	[9]
DWP-05195	DMQKU2F	Neuropathic pain	8E43.0	Phase 2	[10]
SB-705498	DMRYHWI	Rhinitis	FA20	Phase 2	[11]
ABT-102	DMJFWPR	Chronic pain	MG30	Phase 1	[11]
MR-1817	DMVNLGW	Pain	MG30-MG3Z	Phase 1	[12]

Drug(s) Targeting DNA topoisomerase II (TOP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[13]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[14]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[15]
Idarubicin	DMM0XGL	Acute myelogenous leukaemia	2A41	Approved	[13]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Lomefloxacin	DMVRH9C	Bacterial infection	1A00-1C4Z	Approved	[16]
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[13]
Podofilox	DMT2EJP	Condyloma	1A95	Approved	[17]
Enoxacin	DMYTE6L	Acute gonococcal cervicitis		Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[2]
Transient receptor potential cation channel V1 (TRPV1)	TTMI6F5	TRPV1_HUMAN	Antagonist	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024886)
• [2] Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
• [3] GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86.
• [4] Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31.
• [7] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [8] Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6.
• [9] The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759.
• [10] TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 .
• [11] Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030745)
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [14] Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
• [15] Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
• [16] Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
• [17] Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
• [18] Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.